JP2017515795A - 単離されたドナーｍｈｃ由来ペプチド及びその使用 - Google Patents

単離されたドナーｍｈｃ由来ペプチド及びその使用 Download PDF

Info

Publication number
JP2017515795A
JP2017515795A JP2016559818A JP2016559818A JP2017515795A JP 2017515795 A JP2017515795 A JP 2017515795A JP 2016559818 A JP2016559818 A JP 2016559818A JP 2016559818 A JP2016559818 A JP 2016559818A JP 2017515795 A JP2017515795 A JP 2017515795A
Authority
JP
Japan
Prior art keywords
peptide
treg
mhc
acid sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2016559818A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017515795A5 (enExample
Inventor
ギロンノ−，カロル
アネゴン，イグナシオ
ピカーダ，エロディエ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Nantes
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Universite de Nantes
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite de Nantes, Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Universite de Nantes
Publication of JP2017515795A publication Critical patent/JP2017515795A/ja
Publication of JP2017515795A5 publication Critical patent/JP2017515795A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1121—Dendritic cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Transplantation (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
JP2016559818A 2014-04-01 2015-04-01 単離されたドナーｍｈｃ由来ペプチド及びその使用 Ceased JP2017515795A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14163081.4 2014-04-01
EP14163081 2014-04-01
PCT/EP2015/057257 WO2015150491A1 (en) 2014-04-01 2015-04-01 An isolated donor mhc-derived peptide and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019219661A Division JP2020055845A (ja) 2014-04-01 2019-12-04 単離されたドナーｍｈｃ由来ペプチド及びその使用

Publications (2)

Publication Number Publication Date
JP2017515795A true JP2017515795A (ja) 2017-06-15
JP2017515795A5 JP2017515795A5 (enExample) 2018-03-01

Family

ID=50390011

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016559818A Ceased JP2017515795A (ja) 2014-04-01 2015-04-01 単離されたドナーｍｈｃ由来ペプチド及びその使用
JP2019219661A Pending JP2020055845A (ja) 2014-04-01 2019-12-04 単離されたドナーｍｈｃ由来ペプチド及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019219661A Pending JP2020055845A (ja) 2014-04-01 2019-12-04 単離されたドナーｍｈｃ由来ペプチド及びその使用

Country Status (5)

Country Link
US (1) US10105425B2 (enExample)
EP (1) EP3126377B1 (enExample)
JP (2) JP2017515795A (enExample)
ES (1) ES2749073T3 (enExample)
WO (1) WO2015150491A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022516408A (ja) * 2018-12-14 2022-02-28 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） 単離されたＭＨＣ由来ヒトペプチドおよびＣＤ８＋ＣＤ４５ＲＣｌｏｗＴｒｅｇの抑制機能を刺激し、かつ活性化するためのその使用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20181896A1 (es) * 2016-04-06 2018-12-11 Immatics Biotechnologies Gmbh Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra la leucemia mieloide agua (lma) y otros tipos de cancer
WO2019099788A1 (en) * 2017-11-16 2019-05-23 Benaroya Sesearch Institute At Virginia Mason Antigen-specific t regulatory cell assay

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0563485A1 (en) 1992-03-30 1993-10-06 Schering-Plough In vitro generation of human dendritic cells and uses thereof
AU687733B2 (en) 1992-04-01 1998-03-05 Rockefeller University, The Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
US5635363A (en) 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
FR2798128B1 (fr) 1999-09-06 2001-11-16 Inst Nat Sante Rech Med Moyens de detection et de purification de populations lymphocytaires t cd8+ specifiques de peptides presentes dans le contexte hla
DE602004019215D1 (de) * 2004-10-02 2009-03-12 Immatics Biotechnologies Gmbh Immunogene T-Helfer Epitope von menschlichen Tumorantigenen und deren Verwendung in immunotherapeutischen Methoden
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AM. J. TRANSPLANT., vol. 9, JPN6018047779, 2009, pages 697 - 708, ISSN: 0004208789 *
EUR. J. IMMUNOL., vol. 31, JPN6018047777, 2001, pages 1333 - 1339, ISSN: 0004208788 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022516408A (ja) * 2018-12-14 2022-02-28 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） 単離されたＭＨＣ由来ヒトペプチドおよびＣＤ８＋ＣＤ４５ＲＣｌｏｗＴｒｅｇの抑制機能を刺激し、かつ活性化するためのその使用
JP7609775B2 (ja) 2018-12-14 2025-01-07 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） 単離されたＭＨＣ由来ヒトペプチドおよびＣＤ８＋ＣＤ４５ＲＣｌｏｗＴｒｅｇの抑制機能を刺激し、かつ活性化するためのその使用

Also Published As

Publication number Publication date
EP3126377A1 (en) 2017-02-08
EP3126377B1 (en) 2019-09-04
JP2020055845A (ja) 2020-04-09
US20170021001A1 (en) 2017-01-26
ES2749073T3 (es) 2020-03-19
WO2015150491A1 (en) 2015-10-08
US10105425B2 (en) 2018-10-23

Similar Documents

Publication Publication Date Title
CN107148427B (zh) 新型免疫原性肽
JP7320947B2 (ja) 新規な免疫原性ＣＤ１ｄ結合ペプチド
KR102228843B1 (ko) Cd4+ t-세포 반응의 증강을 위한 변형된 에피토프
RU2761653C2 (ru) Пептиды и способы для лечения диабета
JP2020055844A (ja) 単離されたドナーｍｈｃ由来ペプチド及びその使用
Picarda et al. MHC-derived allopeptide activates TCR-biased CD8+ Tregs and suppresses organ rejection
JP2022065022A (ja) 改変ヒト初代血液樹状細胞株を生成するための方法
JP2015142578A (ja) 免疫原性ペプチドおよび免疫障害におけるその使用
JP2023052647A (ja) 標的治療免疫調節のためのＭＨＣクラスＩｂ分子及びペプチドの組合せ
JP2022513021A (ja) 向上した酸化還元酵素モチーフを有する免疫原性ペプチド
JP5916613B2 (ja) 多発性骨髄腫細胞からの抗原ペプチドの同定
JP2018506287A (ja) Ｈｅｒ２／Ｎｅｕ （ＥＲＢＢ２）受容体タンパク質に由来する３６９〜３７７位エピトープに特異的な完全ヒトＴ細胞受容体
JP2020055845A (ja) 単離されたドナーｍｈｃ由来ペプチド及びその使用
WO2020145222A1 (ja) 新規ネオアンチゲン及びそれらを用いたがん免疫治療薬
WO2008113970A2 (en) Peptides
US20060045884A1 (en) Vaccines for autoimmune and infectious disease
JP2023040034A (ja) 耐性を誘導するための操作された細胞
Wu Functions of cDC1 in Mediating CD4+ Help for CD8+ T cells
Sen Targeting Siglecs on Recipient Antigenpresenting Cells With Sialic Acid-Modified Alloantigen to Promote Transplantation Tolerance
JP2019532103A (ja) ペプチドライブラリーおよび使用方法
Gubser Studies of suppression using monoclonal regulatory T cells and the importance of co-receptor Lck coupling ratios for negative selection
Pospori WT1 TCR gene transfer into haematopoietic stem cells: In vivo functional analysis of WT1-specific T cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180118

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180118

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20181114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190301

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191204

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20191204

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20191211

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20191217

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20200207

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20200212

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200915

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20201117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210217

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20210323

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20210427

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20210427

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20210831